6/28/23, 12:41 AM ANT-005 TKA (mid-dose) Pathway Feedback Search Clinical Topics Home Studies ANT 005 TKA (mid-dose) ANT 005 TKA (mid-dose) Disease Knee osteoarthritis Trial question Is abelacimab superior to enoxaparin in the prevention of VTE in patients undergoing total knee arthroplasty? Study design Multi-center Open label RCT Population Characteristics of study participants 80.2% female N = 200 19.8% male 200 patients (161 female, 39 male) Inclusion criteria: patients, aged 18-80 years, who were undergoing elective primary unilateral total knee arthroplasty Key exclusion criteria: active bleeding or high risk of bleeding; history of VTE; an eGFR < 60 mL/min/1.73 m2; clinically significant liver disease Interventions N=99 abelacimab (a single intravenous dose of 75 mg once daily) N=101 enoxaparin (a subcutaneous dose of 40 mg once daily) Primary outcome https://web.pathway.md/studies/recybrXeqnbfmW6W0 1/2 6/28/23, 12:41 AM ANT-005 TKA (mid-dose) Pathway Venous thromboembolism 22.0 % 22 16.5 % 11.0 % Significant decrease 5.5 % 5 NNT = 6 0.0 % Abelacimab Enoxaparin Significant decrease in VTE (5% vs. 22%; ARD -16.8, 95% CI -26 to -7.6) Safety outcomes No significant differences in 1 adverse event, major or clinically relevant nonmajor bleeding, frequency of blood transfusions. Conclusion In patients, aged 18-80 years, who were undergoing elective primary unilateral total knee arthroplasty, abelacimab was superior to enoxaparin with respect to VTE. Reference Peter Verhamme, B Alexander Yi, Annelise Segers et al. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med. 2021 Aug 12;385(7):609-617. Open reference URL https://web.pathway.md/studies/recybrXeqnbfmW6W0 2/2